KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $5.1 million.

  • Biomarin Pharmaceutical's Other Operating Expenses fell 677.28% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 18895.34%. This contributed to the annual value of $10.0 million for FY2024, which is 12616.77% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Other Operating Expenses stood at $5.1 million for Q3 2025, which was down 677.28% from $4.8 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Other Operating Expenses high stood at $108.0 million for Q1 2022, and its period low was -$19.9 million during Q4 2023.
  • Its 5-year average for Other Operating Expenses is $5.8 million, with a median of $193000.0 in 2022.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Other Operating Expenses skyrocketed by 2200669.37% in 2022, and later crashed by 52331.61% in 2023.
  • Biomarin Pharmaceutical's Other Operating Expenses (Quarter) stood at $1.4 million in 2021, then tumbled by 86.28% to $193000.0 in 2022, then crashed by 10409.84% to -$19.9 million in 2023, then surged by 127.46% to $5.5 million in 2024, then dropped by 6.77% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q3 2025, $4.8 million for Q2 2025, and -$2.0 million during Q1 2025.